Loading…
MDxHealth SA is projected to rise to $0.4586 by 2027, a +1% move from its current price of $0.455. MDXH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.4387 | $0.4551 | $0.4721 | +0.02% |
| Aug 6 | $0.4322 | $0.4552 | $0.4794 | +0.04% |
| Aug 7 | $0.4272 | $0.4553 | $0.4851 | +0.06% |
| Aug 8 | $0.4231 | $0.4553 | $0.49 | +0.08% |
| Aug 9 | $0.4196 | $0.4554 | $0.4943 | +0.09% |
| Aug 10 | $0.4164 | $0.4555 | $0.4983 | +0.11% |
| Aug 11 | $0.4135 | $0.4556 | $0.502 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4135 | $0.4556 | $0.502 | +0.13% |
| Week 2 | $0.3977 | $0.4562 | $0.5233 | +0.27% |
| Week 3 | $0.3862 | $0.4568 | $0.5404 | +0.40% |
| Week 4 | $0.3767 | $0.4574 | $0.5554 | +0.53% |
| Week 5 | $0.3687 | $0.458 | $0.569 | +0.67% |
| Week 6 | $0.3616 | $0.4586 | $0.5817 | +0.80% |
| Week 7 | $0.3553 | $0.4592 | $0.5936 | +0.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MDxHealth SA is a commercial-stage precision diagnostics company that provides urologic solutions in the United States, Europe, and internationally. Its testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It offers Genomic Prostate Score (GPS) testing, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment.
The company sells its products through a urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. It was incorporated in 2003, is headquartered in Herstal, Belgium, and was formerly known as OncoMethylome Sciences SA, changing its name to MDxHealth SA in October 2010.
MDxHealth SA trades in the Healthcare sector with current price $0.4256 and a market capitalization of $21.86M. It ranks 4766 by market cap. The stock’s near-term outlook is informed by a year-by-year forecast that shows gradual upside toward the end of the decade, with a 2050 average price of $1.42 and a 2050 maximum of $3.27.
The sequence includes years with neutral sentiment (e.g., 2026) and multiple years labeled BULLISH (notably 2029, 2030, 2032, 2034, 2035, 2040, and 2050). The forecast also shows a 2050 ROI of 234.3 and other mid-term ROIs such as 38.9 in 2029 and 32.1 in 2030.
A major floor 31.7% below — a decisive break under it would weaken the trend.
The nearest floor, 12.1% below — buyers have tended to step in here.
The nearest ceiling, 19.3% above — a clean break opens room to run.
A major ceiling 537.4% above — clearing it would confirm fresh momentum.
Key MDXH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MDXH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.411 | Buy | $0.4129 | Buy |
| MA 10 | $0.4164 | Buy | $0.4182 | Buy |
| MA 20 | $0.4355 | Buy | $0.4435 | Buy |
| MA 50 | $0.5298 | Sell | $0.7087 | Sell |
| MA 100 | $1.41 | Sell | $1.29 | Sell |
| MA 200 | $2.56 | Sell | $1.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.64 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -48.51 | Neutral |
| Williams %R (14) | -53.85 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -4.78 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 46.15 | Neutral |
| TRIX (15) | -1.63 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 40.15 | Neutral |
| Momentum (10) | -0.00 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 0.40 | Buy |
| ADX (14) | 39.00 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 30. The 50-day simple moving average is $0.7862 and the 200-day simple moving average is $2.79. Support sits at $0.40 and resistance at $0.603, with the 30-day price range from $0.3106 to $0.5831. The stock exhibits an annualized volatility of 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.40 | $0.455 | $0.5319 | 0% | Neutral | |
| $0.3545 | $0.4586 | $0.6337 | +1% | Neutral | |
| $0.3816 | $0.5135 | $0.7447 | +13% | Neutral | |
| $0.4242 | $0.59 | $0.888 | +30% | Bullish | |
| $0.4051 | $0.5802 | $0.9007 | +28% | Bullish | |
| $0.3564 | $0.5243 | $0.8361 | +15% | Neutral | |
| $0.3579 | $0.5399 | $0.8817 | +19% | Neutral | |
| $0.3475 | $0.5367 | $0.8956 | +18% | Neutral | |
| $0.3685 | $0.5822 | $0.9909 | +28% | Bullish | |
| $0.4269 | $0.6895 | $1.20 | +52% | Bullish | |
| $0.4215 | $0.7532 | $1.41 | +66% | Bullish | |
| $0.6798 | $1.46 | $3.04 | +221% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.40 | $0.455 | $0.5382 | +0.00% |
| September 2026 | $0.3814 | $0.4554 | $0.5621 | +0.10% |
| October 2026 | $0.3841 | $0.4629 | $0.5796 | +1.64% |
| November 2026 | $0.3596 | $0.4367 | $0.5532 | -5.66% |
| December 2026 | $0.3398 | $0.4156 | $0.5319 | -4.83% |
Click any year to see its month-by-month MDXH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MDXH is projected to trade between $0.40 and $0.5319, averaging $0.455 — a potential gain of 0% from today's $0.455. Price action looks broadly range-bound.
MDxHealth SA's 2027 outlook centres on $0.4586, within a $0.3545 to $0.6337 range. That is up +1% on the projected 2026 average. That marks a +1% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, MDXH could reach as high as $0.7447, with a base case around $0.5135 and support toward $0.3816 — roughly +13% from $0.455. Price action looks broadly range-bound.
Expect MDXH to range from $0.4242 to $0.888 through 2029. The $0.59 average target implies a +30% move from current prices. That is up +15% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MDXH price prediction for 2030 points to an average of $0.5802 (low $0.4051, high $0.9007) — a potential gain of +28% on today's $0.455. Momentum favours further upside here.
In 2031, MDXH is projected to trade between $0.3564 and $0.8361, averaging $0.5243 — a potential gain of +15% from today's $0.455. That is -10% versus the projected 2030 average. A consolidation phase looks the most probable path here.
MDxHealth SA's 2032 outlook centres on $0.5399, within a $0.3579 to $0.8817 range. That is up +3% on the projected 2031 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2033, MDXH could reach as high as $0.8956, with a base case around $0.5367 and support toward $0.3475 — roughly +18% from $0.455. A consolidation phase looks the most probable path here.
Expect MDXH to range from $0.3685 to $0.9909 through 2034. The $0.5822 average target implies a +28% move from current prices. That is up +8% on the projected 2033 average. Momentum favours further upside here.
The MDXH price prediction for 2035 points to an average of $0.6895 (low $0.4269, high $1.20) — a potential gain of +52% on today's $0.455. Buyers look set to stay in control over this stretch.
In 2040, MDXH is projected to trade between $0.4215 and $1.41, averaging $0.7532 — a potential gain of +66% from today's $0.455. That is up +9% on the projected 2035 average. Momentum favours further upside here.
MDxHealth SA's 2050 outlook centres on $1.46, within a $0.6798 to $3.04 range. That is up +94% on the projected 2040 average. That marks a +221% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MDXH today (≈ 2,197.802198 MDXH) could be worth
$3,205.96
+$2,205.96 (+221%) by 2050 · US Dollar
Based on the average projected MDXH price of $1.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MDXHwould be worth at today's price.
$1,000 invested in MDXH on Jul 31, 2025 (≈ 418.410023 MDXH) would be worth
$190.38
-$809.62 (-81.0%) today · 0.19× · US Dollar
Based on a MDXH entry price of $2.39 vs. today's $0.455.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.41 | $1,109.76 | +11.0% |
| 1 month ago | $0.507 | $897.44 | -10.3% |
| 3 months ago | $2.06 | $220.87 | -77.9% |
| 6 months ago | $3.53 | $128.9 | -87.1% |
| 1 year ago | $2.39 | $190.38 | -81.0% |
| All time (4.7y) ago | $12 | $37.92 | -96.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MDXH forecast.
Our base-case forecast reaches $0.91 around 2050.
Implied market cap at $0.91: $46.74M
Over the multi-year horizon, sentiment shifts toward BULLISH in several later years, with 2029 and 2030 explicitly labeled BULLISH. The forecast shows 2029 average $0.5909 and 2030 average $0.5624, with ROIs of 38.9 and 32.1, respectively. By 2032, 2034, 2035, 2040, and 2050, sentiment is also BULLISH, and the 2050 average price is $1.42 with a max of $3.27 and ROI of 234.3.
The 2050 max price is $3.27, and the 2040 max is $1.44, while 2035 max is $1.33. These are estimates, not guarantees, and reflect potential paths for the asset under the provided forecast.
Tap a question to reveal the answer.
The 2030 average price is $0.5624, with a min of $0.3628 and a max of $0.9416, and an ROI of 32.1. The sentiment for 2030 is BULLISH.
Forecasts show several bullish years (e.g., 2029 and 2030) with positive ROIs (38.9 in 2029 and 32.1 in 2030) and a long-term bullish outlook in 2040 and 2050, but there is also a neutral stance in earlier years and 2026. These are estimates, not guarantees.
Yes. The forecast shows higher price possibilities over time, with 2035 max $1.33, 2040 max $1.44, and 2050 max $3.27.
The current price is $0.4256.
RSI(14) is 30, the SMA50 is $0.7862, and the SMA200 is $2.79. Support is at $0.40 and resistance at $0.603, with a 30-day range of $0.3106 to $0.5831. The asset also shows an annualized volatility of 90%.
MDxHealth SA Community Discussion
0Share your MDxHealth SA price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.